$BIOA News
Last published 11h ago
- 11h agoBIOALeqembi® Pen subcutaneous treatment launched in JapanPR NewswireBioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today announced that Leqembi Pen, the subcutaneous formulation of lecanemab, has...
- 11h agoBIOALeqembi® Pen subcutaneous treatment launched in JapanPR NewswireBioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today announced that Leqembi Pen, the subcutaneous formulation of lecanemab, has...
- 1d agoBIOASTIFEL 2026 HEALTHCARE CONFERENCE - BIOAGE LABS INCEarnings Call TranscriptsAre you on? Yes. Okay. Good afternoon, everyone, and welcome to the BioAge Lab's presentation. BioAGE, as you know, is targeting NLRP3 to address diseases of aging and inflammation, and with us today is B.J. Sullivan, Ch
- 1d agoBIOABIOAGE LABS, INC. STIFEL 2026 HEALTHCARE CONFERENCE - BIOAGE LABS INCEarnings Call TranscriptsAre you on? Yes. Okay. Good afternoon, everyone, and welcome to the BioAge Lab's presentation. BioAGE, as you know, is targeting NLRP3 to address diseases of aging and inflammation, and with us today is B.J. Sullivan, Ch
- 1d agoBIOASTIFEL 2026 HEALTHCARE CONFERENCE - BIOAGE LABS INCEarnings Call TranscriptsAre you on? Yes. Okay. Good afternoon, everyone, and welcome to the BioAge Lab's presentation. BioAGE, as you know, is targeting NLRP3 to address diseases of aging and inflammation, and with us today is B.J. Sullivan, Ch
- 1w agoBIOABioAge Labs, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoBIOABioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswireFirst participant dosed in QUELL-DME, a Phase 2 trial of BGE-102, a potential best-in-class oral NLRP3 inhibitor, in diabetic macular edema; topline results anticipated in the second half of 2027 QUELL-CV, a Phase 2
- 1w agoBIOABioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswireFirst participant dosed in QUELL-DME, a Phase 2 trial of BGE-102, a potential best-in-class oral NLRP3 inhibitor, in diabetic macular edema; topline...
- 2w agoBRCTFBIOABioArctic's Nomination Committee appointedPR NewswireSTOCKHOLM, October 30, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced the composition of its Nomination Committee for the 2027 Annual General Meeting. The Nomination Committee has
- 1mo agoBIOADeep Origin Announces Multi-Target AI-Driven Drug Discovery Collaboration with BioAge Labs; Validated Hits Confirmed against First TargetGlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Deep Origin today announced a multi-target AI-driven drug discovery collaboration with BioAge Labs, Inc. (NASDAQ:BIOA), a clinical-stage biopharmaceutical
- 1mo agoBIOASTIFEL 2026 VIRTUAL CARDIOMETABOLIC FORUM - BIOAGE LABS INCEarnings Call TranscriptsHi, good afternoon, and welcome to the BioAge session. It's our pleasure to have B.J. Sullivan, Chief Strategy Officer of the company. BioAGE is developing an NLRP3 inhibitor, which has CNS penetrant properties for both
- 1mo agoBIOASTIFEL 2026 VIRTUAL CARDIOMETABOLIC FORUM - BIOAGE LABS INCEarnings Call TranscriptsHi, good afternoon, and welcome to the BioAge session. It's our pleasure to have B.J. Sullivan, Chief Strategy Officer of the company. BioAGE is developing an NLRP3 inhibitor, which has CNS penetrant properties for both
- 1mo agoBIOAFirst patient treated with Leqembi® (lecanemab) in SwedenPR NewswireBioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that Leqembi is now available at a private clinic in Sweden and that the first patient ...
- 1mo agoBIOAFirst patient treated with Leqembi® (lecanemab) in SwedenPR NewswireBioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that Leqembi is now available at a private clinic in Sweden and that the first patient ...
- 1mo agoBIOABioAge Labs - 1774121 - BIOAGE LABS INCEarnings Call TranscriptsHello, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Mike Goltz, one of the biotech analysts here, and it's my pleasure to introduce the team from BioAge Labs. To my immediat
- 1mo agoBIOABioAge Labs - Morgan Stanley 24th Annual Global Healthcare Conference - BIOAGE LABS INCEarnings Call TranscriptsHello, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Mike Goltz, one of the biotech analysts here, and it's my pleasure to introduce the team from BioAge Labs. To my immediat
- 1mo agoBIOAMorgan Stanley 24th Annual Global Healthcare Conference - BioAge Labs - BIOAGE LABS INCEarnings Call TranscriptsHello, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Mike Goltz, one of the biotech analysts here, and it's my pleasure to introduce the team from BioAge Labs. To my immediat
- 1mo agoBIOALeqembi® Pen subcutaneous formulation approved in JapanPR NewswireBioArctic AB (publ)'s (NASDAQ STOCKHOLM: BIOA B) partner Eisai announced today that the subcutaneous autoinjector formulation of Leqembi (known as...
- 1mo agoBIOALeqembi® Pen subcutaneous formulation approved in JapanPR NewswireBioArctic AB (publ)'s (NASDAQ STOCKHOLM: BIOA B) partner Eisai announced today that the subcutaneous autoinjector formulation of Leqembi (known as...
- 2mo agoBIOABioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular EdemaGlobeNewswireRandomized, controlled, approximately 180-participant trial evaluates oral BGE-102 as monotherapy and in combination with anti-VEGF therapy Primary endpoint is change in best-corrected visual acuity at week 12 Topline
- 2mo agoBIOABioAge Labs to Present at Upcoming Investor ConferencesGlobeNewswireEMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for
- 2mo agoBIOANumber of shares and votes in BioArctic AB (publ) as of August 31, 2026PR NewswireBioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 20,200 Class B shares during August for delivery of shares to...
- 2mo agoBIOANumber of shares and votes in BioArctic AB (publ) as of August 31, 2026PR NewswireBioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 20,200 Class B shares during August for delivery of shares to...
- 2mo agoBIOALeqembi Iqlik® for initiation treatment launched in the USPR NewswireBioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today announced that lecanemab-irmb subcutaneous injection (US brand name: Leqembi...
- 2mo agoBIOALeqembi Iqlik® for initiation treatment launched in the USPR NewswireBioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today announced that lecanemab-irmb subcutaneous injection (US brand name: Leqembi...
- 2mo agoBIOABioArctic and Mesenkia enter oncology research collaborationPR NewswireBioArctic AB (publ) (NASDAQ Stockholm: BIOA B) and Mesenkia Therapeutics announced today that the companies have signed a research collaboration...
- 2mo agoBIOABioArctic and Mesenkia enter oncology research collaborationPR NewswireBioArctic AB (publ) (NASDAQ Stockholm: BIOA B) and Mesenkia Therapeutics announced today that the companies have signed a research collaboration...
- 2mo agoBIOAInvitation to presentation of BioArctic's second quarter report for April - June 2026 on August 26 at 9:30 a.m. CESTPR NewswireBioArctic AB (publ) (NASDAQ Stockholm: BIOA B) will publish the company's second quarter report for April - June 2026 on Wednesday, August 26, 2026,...
- 2mo agoBIOAInvitation to presentation of BioArctic's second quarter report for April - June 2026 on August 26 at 9:30 a.m. CESTPR NewswireBioArctic AB (publ) (NASDAQ Stockholm: BIOA B) will publish the company's second quarter report for April - June 2026 on Wednesday, August 26, 2026,...
- 3mo agoBIOABioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswireFirst participant dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 measuring inflammatory and cardiometabolic biomarkers; topline data anticipated in the second half of 2026 QUELL-DME, Phase
- 3mo agoBIOASales of Leqembi® totaled 29.3 billion yen in the second quarter 2026PR NewswireBioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the second quarter...
- 3mo agoBIOASales of Leqembi® totaled 29.3 billion yen in the second quarter 2026PR NewswireBioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the second quarter...
- 4mo agoBIOAMore than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026PR NewswireBioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented results from the real-world Lecanemab in Early Alzheimer's Disease...
- 4mo agoBIOAMore than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026PR NewswireBioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented results from the real-world Lecanemab in Early Alzheimer's Disease...
- 4mo agoBIOAHitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk ReductionPR NewswireShanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH), congratulates its partner BioAge Labs, Inc. ("BioAge", NASDAQ: BIOA),...
- 4mo agoBIOAFDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's diseasePR NewswireBioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the US Food and Drug Administration (FDA) has approved a...
- 4mo agoBIOAFDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's diseasePR NewswireBioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the US Food and Drug Administration (FDA) has approved a...
- 4mo agoBIOANew clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's diseasePR NewswireBioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented new data at the 2026 Alzheimer's Association International Conference...
- 4mo agoBIOANew clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's diseasePR NewswireBioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented new data at the 2026 Alzheimer's Association International Conference...
- 4mo agoBIOANew clinical and real-world evidence on Lecanemab to be presented at AAIC conference 2026PR NewswireBioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai will present new clinical and real-world evidence on lecanemab (Leqembi®) at the...
- 4mo agoBIOANew clinical and real-world evidence on Lecanemab to be presented at AAIC conference 2026PR NewswireBioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai will present new clinical and real-world evidence on lecanemab (Leqembi®) at the...
- 4mo agoBIOABioArctic and Lilly sign research and collaboration agreement combining Lilly compound with BioArctic's BrainTransporter™ technologyPR NewswireBioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the company has entered into a research and collaboration agreement with Eli...
- 4mo agoBIOABioArctic and Lilly sign research and collaboration agreement combining Lilly compound with BioArctic's BrainTransporter™ technologyPR NewswireBioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the company has entered into a research and collaboration agreement with Eli...
- 5mo agoBIOABioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular RiskGlobeNewswireRandomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral doses of BGE-102 in participants with elevated systemic inflammation and additional cardiovascular risk factors Primary
- 5mo agoBIOANumber of shares and votes in BioArctic AB (publ) as of May 29, 2026PR NewswireBioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 5,000 Class B shares during May for delivery of shares to...
- 5mo agoBIOANumber of shares and votes in BioArctic AB (publ) as of May 29, 2026PR NewswireBioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 5,000 Class B shares during May for delivery of shares to...
- 5mo agoBIOABulletin from the Annual General Meeting in BioArctic AB (publ)PR NewswireToday, BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) held its Annual General Meeting in Stockholm, whereby the following resolutions were made....
- 5mo agoBIOABulletin from the Annual General Meeting in BioArctic AB (publ)PR NewswireToday, BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) held its Annual General Meeting in Stockholm, whereby the following resolutions were made....
- 5mo agoBIOABioArctic's partner Eisai presents sales simulation of potential future sales of Leqembi® at its Investor Relations DayPR NewswireBioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published a presentation including a simulation[1] of potential future sales for ...
- 5mo agoBIOABioArctic's partner Eisai presents sales simulation of potential future sales of Leqembi® at its Investor Relations DayPR NewswireBioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published a presentation including a simulation[1] of potential future sales for ...